Novavax

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Novavax reports strong revenue growth, focuses on fall vaccine launch

Novavax aims to deliver a competitive vaccine for the fall season, optimize cash flow, and mitigate risks. The company's focus on cost reduction and strategic investments align with its goal of long-term growth.

Novavax reports positive Phase 2 results and revenue guidance

Novavax's Q1 2023 earnings call highlighted positive Phase 2 trial results, revenue guidance, and cost-saving initiatives.
The company's focus on vaccine development, workforce reductions, and strategic collaborations bode well for future growth.
Challenges include ongoing arbitration with Gavi and managing global restructuring impacts on R&D efforts.
Opportunities lie in revenue growth, market expansion with Nuvaxovid, and leveraging technology for a robust vaccine portfolio.

Novavax reports robust Q2 earnings, anticipates strong revenue growth

Novavax is on track to deliver an updated vaccine for the fall season and expects strong revenue growth in 2023. They have significantly reduced liabilities, signed key agreements, and are investing in combination vaccines. Despite challenges ahead, the company remains committed to delivering successful performance.

Novavax reports strong Q3 results, eyes market share growth

Novavax is strategically positioned to drive long-term profitability with efficient cost structures.
The company's focus on innovation, cost reduction, and market expansion bodes well for future growth.
Despite challenges, Novavax's strong financial position and technology platform offer resilience and growth opportunities.

Novavax reduces expenses, targets growth with new vaccines in 2024

Novavax made significant strides in reducing expenses and liabilities in 2023, positioning for growth in 2024.
The company's focus on advancing its combination vaccine program and improving market share presents opportunities for expansion.
Challenges include improving U.S. market performance, addressing remaining liabilities, and securing regulatory authorizations.
Efforts to streamline operations, enhance customer engagement, and offer convenient products are key to Novavax's success in 2024.

Novavax reports strong Q1 earnings, secures $1.3B Sanofi deal

Novavax's Q1 2024 performance shows promising revenue growth, expense reduction, and strategic partnership with Sanofi driving cash flow improvements.
While facing challenges in managing the multibillion-dollar opportunity and regulatory pathways, Novavax is well-positioned to capitalize on revenue opportunities.
The company's focus on optimizing existing agreements, expanding partnerships, and exploring new areas like RSV sets a strong foundation for future growth.

Novavax reports $85M revenue, focuses on cost reduction and partnerships

Novavax's Q3 2024 performance showcased revenue growth and strategic cost reduction efforts.
Key strengths include a strong partnership with Sanofi and a focus on pipeline development.
Challenges ahead involve cost alignment, trial design complexities, and maintaining margins.
Opportunities lie in new pipeline programs, financial gains from partnerships, and cost optimization.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax's (NVAX) COVID-19 vaccine candidate, NVX-CoV2373, shows an overall efficacy of 90% in the phase III PREVENT-19 study in the United States and Mexico.

Novavax's (NVAX) COVID-19 Vaccine Shows 90% Efficacy in US Study

Dynavax Technologies

Vaxart

The declines appear to be caused simply by volatility that's common with small biotech stocks.

Why COVID Vaccine Stocks Dynavax, Novavax, and Vaxart Are Sinking Today

If it is approved, the Novavax Covid-19 vaccine could sell for less than the versions based on messenger-RNA technology that are already in use.

Novavax Stock's Decline Doesn't Tell the Real Story of Its Vaccine Data

Salesforce

Intel

Microsoft

UnitedHealth Group

Q.ai runs daily factor models to get the most up-to-date reading on stocks and ETFs. Today, our deep-learning algorithms have identified Novavax Inc and Salesforce.com among others.

Artificial Intelligence Identifies Novavax, Inc Among Today's Trending Stocks

Shares of Novavax Inc. were down 0.9% in trading on Tuesday, the day after the company said a study evaluating co-vaccination against COVID-19 and the flu demonstrated similar efficacy to administering Novavax's experimental COVID-19 shot alone. "Separate health care visits to cover both COVID-19 and influenza vaccinations will be burdensome," a Novavax executive said in a news release.

Novavax says efficacy of COVID-19 vaccine isn't affected when co-administered with the flu shot

Novavax stock has gained about 12% over the last five trading days and has rallied by a solid 73% over the last month, largely recovering from the sell-off in late April and early May when the company said that it would delay seeking authorization of its Covid-19 shot to the third quarter of this.

Novavax Vaccine Updates: U.S. Phase 3 Data, Efficacy Against Beta Variant

Novavax, Inc. (NASDAQ:NVAX) said its COVID-19 vaccine was 90% effective in late-stage trials and was also tested in combination with an approved jab for influenza. The jab was analysed on 29,960 participants across 119 sites in the US and Mexico, showing 100% protection against moderate and severe disease and 90% efficacy overall.

Novavax says COVID-19 vaccine 90% effective, also tested in combination with influenza jab

Novavax Inc (NASDAQ: NVAX) announced its experimental COVID-19 vaccine remained effective when coadministered with an approved flu shot. Researchers are interested in studying coadministration and the associated safety & efficacy of giving multiple vaccines to a person during one visit to ease logistics and help patients catch up on missed vaccinations, especially amid the pandemic.

Novavax's COVID-19 Vaccine, Flu Shot Co-administration Preserved Efficacy, Likely 'Viable Strategy,' Company Says

The shares skyrocketed last year. But more catalysts are just ahead.

3 Great Reasons to Buy Novavax

Shares of Novavax Inc. ( NVAX , Financial) closed slightly lower on Monday despite increasing as much as 7% at market open on the back of reporting strong results for its Phase 3 clinical trial of its Covid-19 vaccine candidate.

Novavax Reports 90% Effectiveness Rate for Covid-19 Vaccine

GAITHERSBURG, Md., June 14, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced data from the first co-administration study of a SARS-CoV-2 vaccine candidate [Novavax, NVX-CoV2373] and an approved influenza vaccine [Seqirus, adjuvanted, trivalent seasonal influenza vaccine (aTIV) or a cell-based, quadrivalent seasonal influenza vaccine (QIVc)].

Novavax Announces Positive Results from First Study of Influenza Vaccine and COVID-19 Vaccine Candidate Administered Simultaneously

Pfizer

It was "better late than never" for Novavax, Inc. (NASDAQ: NVAX), as the biopharma finally got around to announcing interim results from the U.S. and Mexico leg of the Phase 3 study of NVX-CoV2371, its vaccine candidate against the novel coronavirus. Here's a comparative perspective of the vaccine candidates from Novavax, and the frontrunners, namely Pfizer Inc. (NYSE: PFE)-BioNTech SE (NASDAQ: BNTX) and Moderna, Inc. (NASDAQ: MRNA), both of which have authorized vaccines in the market.

Novavax Vs. Pfizer Vs.

Novavax's CEO said he believes boosters will be the company's “biggest market” in the U.S. once it receives regulatory approval for its COVID-19 vaccine.

Novavax CEO: COVID-19 booster to be 'biggest market' in US

American biotechnology company Novavax says its COVID-19 vaccine has shown to have 90.4% effectiveness in a Phase 3 clinical trial. American biotechnology company Novavax said today that the COVID-19 vaccine it's developing has shown to have 90.4% effectiveness in a Phase 3 clinical trial conducted in the United States and Mexico.

Novavax eyes bringing its COVID-19 vaccine to the U.S. market

Novavax Inc (NASDAQ: NVAX) said on Monday its candidate COVID-19 vaccine showed 93% efficacy in its U.S. late-stage trial. The results of the clinical trial also confirmed the vaccine to be effective against a range of predominant Coronavirus variants.

Novavax COVID-19 vaccine shows over 90% efficacy in the U.S. late-stage trial

Orphazyme A/S

Avenue Therapeutics

Novavax, Inc. (NASDAQ: NVAX), Orphazyme A/S (NASDAQ: ORPH) and Avenue Therapeutics, Inc. (NASDAQ: ATXI) are among the biggest movers among biopharma stocks Monday. Novavax Finally Releases Phase 3 COVID-19 Results: After a protracted delay, Gaithersburg, Maryland-based Novavax reported preliminary results showing its coronavirus candidate NVX-CoV2371 met the primary endpoint of the Phase 3 PREVENT trial in the U.S. and Mexico.

Why Novavax, Orphazyme, Avenue Therapeutics Shares Are Moving Monday

Novavax, Inc. (NASDAQ:NVAX) stepped into the spotlight today, after a late-stage trial showed its Covid-19 to be 90% effective overall, with 100% protection against moderate and severe disease.

Options Traders Take a Shot at NVAX Following Vaccine Update

Novavax shares climbed as much as 9% on Monday after the company said a late-stage study of its experimental COVID-19 vaccine showed efficacy of more than 90% in nearly 30,000 people. The results move the company closer to seeking authorization for its use in the US.  The company said it plans on filing for regulatory approval of NVX-CoV2373 with the Food and Drug Administration in the third quarter and upon receiving clearance it would remain on track to reach manufacturing capacity of 100 million doses per month by the end of the third quarter. It also foresees hitting manufacturing capacity of 150 million doses per month by the end of the fourth quarter.

Novavax climbs 9% after clinical trial shows the firm's COVID-19 vaccine is 90% effective (NVAX)

The company said it will seek approval for its vaccine in the quarter beginning in July.

Novavax Study Shows Covid Vaccine 90% Effective

The stock price of Novavax, Inc. (NASDAQ: NVAX) increased by over 5% during intraday trading this morning. These are the details.

NVAX Stock Price: Over 5% Increase Details

Novavax reported positive results from its long-awaited Covid-19 vaccine trials. With G7 leaders promising more vaccines for poorer countries, NVAX could be a beneficiary.

NVAX Stock: The Huge Vaccine News Helping Novavax Shoot Higher Today

Hello, Welcome to Insider Healthcare. I'm Lydia Ramsey Pflanzer, and today in healthcare news:

Novavax says its coronavirus shot is 90% effective

Novavax, Inc. (NASDAQ: NVAX) shares are trading higher by 9.8% at $230.25 Monday morning after the company announced positive Phase 3 trial results for its COVID-19 vaccine.  According to Novavax, its COVID-19 vaccine has 93% efficacy against predominantly circulating variants of concern and variants of interest and 91% efficacy in high-risk populations.

Why Novavax Stock Is Moving Today

Novavax Inc (NASDAQ: NVAX) has finally completed its U.S. Phase 3 trial for its protein-based COVID-19 vaccine candidate. Overall efficacy in the study hit 90.3% across nearly 30,000 patients in the U.S. and Mexico, with a total of 77 cases observed.

Long-awaited Novavax's COVID-19 Vaccine Results Hit 90% Efficacy In Pivotal US Trial, 100% Efficacy Against Moderate, Severe Infection

The company on Monday said a late-stage trial of its coronavirus vaccine would be submitted for approval in the third quarter, an encouraging sign that there would be further doses of a medication to fight the pandemic.

News for Novavax Stock (NVAX)